Abstract:Abstract Abstract 1081 Our previous study has demonstrated that oral tetra-arsenic tetra-sulfide (As4S4) alone is highly effective and safe in both induction and maintenance therapy in acute promyelocytic leukemia (APL) (Dao-Pei Lu et al., Blood 2002; 99: 3136). Triple-agent treatment with As4S4, all-trans retinoid acid (ATRA) and low-dose chemotherapy has achieved expeditiously consecutive complete remission (CR) without death during induction, and it has also improved leukemia-free survival (LFS) (Tong Wu et al., ASH abstract 591 2007). To learn the efficacy and safety of As4S4 and arsenic trioxide (ATO), a total of 88 consecutive cases of newly diagnosed APL patients who have been treated with triple-agent regimen with arsenic, either As4S4 (n=42) or ATO (n=46), ATRA and low-dose chemotherapy at Beijing Dao-Pei Hospital were analyzed retrospectively. Major clinical characteristics in two groups were similar. Purified natural oral As4S4 (Dao-Pei Lu's Lab) or commercially available intravenous ATO were used. The regimens for induction, consolidation and maintenance therapy have been reported previously. All 88 patients attained hematological CR (HCR) after induction therapy without early death. A total of 84 cases were monitored for PML/RARA fusion transcript by RQ-PCR. Molecular CR (MCR) reached in all evaluable cases (100%) in As4S4 group and 93.5% of cases in ATO group. In As4S4 group, 3-year and 5-year LFS rates were all 100% with a median follow-up of 57 months (range, 12–103 months). In ATO group, however, 5 cases relapsed and 2 patients died with a median follow-up of 36 months (range, 12–96 months). The 3-year and 5-year LFS rates were both 86.6%. The difference of LFS between As4S4 and ATO groups were remarkable (p=0.028). Three-year and 5-year overall survival (OS) rates were all 100% in As4S4 group, 96.7% and 88.6% in ATO group respectively. Statistically there was no significant difference (p=0.1015). The side effects in As4S4 group were mild and all patients could continue the therapy. However, a total of 15 side events in ATO group including hepatic, cardiac or lung complications led to discontinuation of therapy. Our encouraging clinical results indicate that arsenic, either As4S4 or ATO in combination with ATRA and low-dose chemotherapy is highly effective in the induction of both HCR and MCR in newly diagnosed APL patients. As4S4 containing triple-agent protocol has better results in the prevention of relapse and improvement of LFS, and has less toxicity. Our clinical study has shown for the first time that all consecutive newly diagnosed cases of APL have achieved long-term LFS with As4S4 containing triple-agent regimen, which are significantly better than that of ATO containing one. Disclosures: No relevant conflicts of interest to declare.

Comparative Proteome Study of Apoptosis Induced by As4S4 in Retinoid Acid Resistant Human Acute Promyelocytic Leukemia NB4-R1 Cells

[Mechanism of Tetra-Arsenic Tetra-Sulfide in Inducing Apoptosis of Acute Promyelocytic Leukemia Cells].

The Clinical Efficacy of All-Trans Retinoic Acid Plus Arsenic Trioxide in 177 Newly Diagnosed Acute Promyelocytic Leukemia Patients

Long-Term Efficacy Of Low-Dose All-Trans Retinoic Acid Plus Minimal Chemotherapy Induction Followed By The Addition Of Intravenous Arsenic Trioxide Post-Remission Therapy In Newly Diagnosed Acute Promyelocytic Leukaemia

Long-Term Efficacy of Low-Dose All-Trans Retinoic Acid Plus Individually Adapted Chemotherapy Induction Followed by Arsenic Trioxide Based Post-Remission Therapy in Adults with Newly Diagnosed Acute Promyelocytic Leukemia

[Study on Matrine Alleviating Retinoic Acid Resistance in Acute Promyelocytic Leukemia].

Arsenic Trioxide Induces Not Only Apoptosis but Also Autophagic Cell Death in Leukemia Cell Lines Via Up-Regulation of Beclin-1

Tetra-Arsenic Tetra-Sulfide For The Treatment Of Acute Promyelocytic Leukemia: A Pilot Report

[Experimental study of low dose arsenic trioxide in treatment of patients with acute promyelocytic leukemia].

Effect of tetra-arsenic tetra-sulfide on Caspase-3 activity in acute promyelocytic leukemia cells

[Change of PML/PML-RARalpha Protein During Treatment with Tetraarsenic Tetrasulfide (as4s4) in Patients with Acute Promyelocytic Leukemia].

[Can As2O3 Improve the Prognosis of Childhood Acute Promyelocytic Leukemia?--a Single Center Experience].

CD71-mediated Liposomal Arsenic-nickel Complex Combined with All-trans Retinoic Acid for the efficacy of Acute Promyelocytic Leukemia

Berbamine Selectively Induces Apoptosis of Human Acute Promyelocytic Leukemia Cells Via Survivin-Mediated Pathway

Efficacy and resistance of molecularly targeted therapy for myeloid malignancies Mechanisms of action and resistance to all-trans retinoic acid ( ATRA ) and arsenic trioxide ( As 2 O 3 ) in acute promyelocytic leukemia

Arsenic Containing Triple-Agent Therapy for Acute Promyelocytic Leukemia-Comparison of Tetra-Arsenic Tetra-Sulfide Vs. Arsenic Trioxide in the Long-Term Follow-up at a Single Hospital.

Mutations of Epigenetic Modifier Genes As A Poor Prognostic Factor in Acute Promyelocytic Leukemia under Treatment with All-Trans Retinoic Acid and Arsenic Trioxide

Investigation on the Effect of Arsenic Trioxide on the Apoptosis- associated Gene Expression Profile of NB4 Cells by Human Apoptosis and Cell Cycle Gene Array

Proteomic analysis of apoptosis initiation induced by all-trans retinoic acid in human acute promyelocytic leukemia cells.

Comparative Proteomic Analysis of All-Trans-retinoic Acid Treatment Reveals Systematic Posttranscriptional Control Mechanisms in Acute Promyelocytic Leukemia

Effect of Ascorbic Acid Combined with Arsenic Trioxide on Apoptosis and Differentiation in Myelocytic Leukemia Cell Lines